These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11459206)

  • 1. Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.
    Budman DR; Johnson R; Barile B; Bowsher RR; Vinciguerra V; Allen SL; Kolitz J; Ernest CS; Kreis W; Zervos P; Walling J
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):525-31. PubMed ID: 11459206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
    Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
    Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
    Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG
    J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
    Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
    Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.
    Sessa C; de Jong J; D'Incalci M; Hatty S; Pagani O; Cavalli F
    Clin Cancer Res; 1996 Jul; 2(7):1123-7. PubMed ID: 9816277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
    Rinaldi DA; Burris HA; Dorr FA; Woodworth JR; Kuhn JG; Eckardt JR; Rodriguez G; Corso SW; Fields SM; Langley C
    J Clin Oncol; 1995 Nov; 13(11):2842-50. PubMed ID: 7595747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet.
    Habeck LL; Chay SH; Pohland RC; Worzalla JF; Shih C; Mendelsohn LG
    Cancer Chemother Pharmacol; 1998; 41(3):201-9. PubMed ID: 9443636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.
    Ratliff AF; Wilson J; Hum M; Marling-Cason M; Rose K; Winick N; Kamen BA
    J Clin Oncol; 1998 Apr; 16(4):1458-64. PubMed ID: 9552052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.
    Fyfe D; Price C; Langley RE; Pagonis C; Houghton J; Osborne L; Woll PJ; Gardner C; Baguley BC; Carmichael J;
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):333-7. PubMed ID: 11345650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol.
    Muggia FM; Synold TW; Newman EM; Jeffers S; Leichman LP; Doroshow JH; Johnson K; Groshen S
    J Natl Cancer Inst; 1996 Oct; 88(20):1495-6. PubMed ID: 8841028
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
    Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
    Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
    Weiss GR; Sarosy GA; Shenkenberg TD; Williams T; Clendeninn NJ; Von Hoff DD; Woolley JL; Liao SH; Blum MR
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1867-73. PubMed ID: 2632268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.